Elliott J, Suessmith Y, Scott LM, Nahlik K, McMullin MF, Constantinescu SN, Green AR, Johnston JA. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica 2009; in press.

 

Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJP, Green AR, Alexander DR. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N. Engl. J. Med. 2008; 359: 2778-2789.

 

Bercovich D§, Ganmore I§, Scott LM, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Binder V, Borkhardt A, Trka J, Bielorei B, Avigad S, Stark B, Bourquin JP, Smith O, Kempski H, Green AR, Izraeli S. Unique activating mutations of JAK2 in the acute lymphoblastic leukaemias of Down Syndrome. Lancet 2008; 372: 1484-1492.

 

Jones AV, Cross NC, White HE, Green AR, Scott LM. Rapid identification of JAK2 mutations using high resolution melting curve (HRM) analysis. Haematologica 2008; 93: 1560-1564.

 

Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, HarrisonCN, Green AR. Clinical significance of MPL mutations in essential thrombocythemia: analysis of the PT-1 cohort. Blood 2008; 112: 141-149.

 

Kouroupi E, Zoi K, Parquet N, Zoi C, Kiladjian JJ, Grigoraki V, Vainchenker W, Lellouche F, Marzac C, Schlageter MH, Dosquet C, Scott LM, Fenaux P, Loukopoulos D, Chomienne C, Cassinat B. Mutations in exon 12 of the JAK2 gene are essentially clustered in JAK2 V617F-negative polycythaemia vera patients. Br. J. Haematol. 2008; 142: 676-679.

 

Percy MJ§, Scott LM§, Erber WN, Harrison CN, Reilly JT, Jones FGC, Green AR, McMullin MF. JAK2 gain of function mutations occur commonly in idiopathic erythrocytosis patients with low serum erythropoietin. Haematologica 2007; 92: 1607-1614.

 

Scott LM, Beer PA, Bench AJ, Erber WN, Green AR. Prevalence of JAK2 V617F and exon 12 mutations in patients with polycythemia vera. Br. J. Haematol. 2007; 139: 511-512.

 

Banerjee ER, Priestley GV, Jiang Y, Henderson WR, Scott LM, Papayannopoulou T. Lack of redundancy of a4 versus b2 for asthma development but not for optimal sensitization. Exp. Hematol. 2007; 35: 605-617.

 

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, McMullin MF, Harrison CN, Erber WN, Warren AJ, Gilliland DG, Lodish HF, Green AR. Gain-of-function mutations in JAK2 exon 12 reveal a variant of polycythemia vera. N. Engl. J. Med. 2007; 356: 459-468.

 

Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJP, Kusec R, Hasselbach HC, Giraudier S, Le Bousse-Kerdiles MC, Greisshammer M, Reilly JT, Harrison CN, Green AR. Timing of JAK2 V617F mutation in MPDs and role of co-operating mutations: clonality, cytogenetics and leukemic transformation. Blood 2006; 108: 3548-3555.

 

Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435-2458.

 

Vassiliou GS, Campbell PJ, Li J, Roberts I, Swanton S, Huntly BJ, Fourouclas N, Baxter EJ, Munroe LR, Culligan D, Scott LM, Green AR. An acquired translocation in JAK2 V617F-negative essential thrombocythemia associated with autosomal spread of X-inactivation. Haematologica 2006; 91: 1100-1104.

 

Priestley G, Scott LM, Ulyanova T, Papayannopoulou T. Lack of a4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood 2006; 107: 2959-2967.

 

Campbell PJ§, Scott LM§, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott M, Vassiliou GS, Milligan D, Smith S, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.

 

Campbell PJ§, Scott LM§, Bench AJ, Green AR, Erber WN. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. In Myeloid Leukemia: Methods and Protocols; Methods in Molecular Medicine 2005; 125: 253-264.

 

Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, Wooster R, Stratton MR, Futreal PA, Green AR. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the myeloproliferative disorders. Blood 2005; 106: 2920-2921.

 

Ulyanova T§, Scott LM§, Priestley GV, Jiang Y, Nakamoto B, Koni P, Papayannopoulou T. VCAM-1 expression in adult hematopoietic and non-hematopoietic cells is controlled by tissue inductive signals and reflects their developmental origin. Blood 2005; 106: 86-94.

 

Baxter EJ§, Scott LM§, Campbell PJ§, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Cancer Genome Project, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.

 

Peterson KR, Fedosyuk H, Zelenchuk L, Nakamoto B, Yannaki E, Stamatoyannopoulos G, Ciciotte S, Peters LL, Scott LM, Papayannopoulou T. Transgenic cre expression mice for the generation of erythroid-specific gene alterations. Genesis 2004; 39: 1-9.

 

Scott LM, Priestley GV, Papayannopoulou T. Deletion of a4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol. Cell. Biol. 2003; 23: 9349-9360.

 

Papayannopoulou T, Priestley G, Nakamoto B, Zafiropoulos V, Scott LM. Hierarchy of molecular pathways in bone marrow homing: dominant role of a4b1 over b2 integrins and selectins. Blood 2001; 98: 2403-2411.

Papayannopoulou T, Priestley GV, Nakamoto B, Zafiropoulos V, Scott LM, Harlan JM. Synergistic mobilization of hemopoietic progenitor cells using concurrent b1 and b2 integrin blockade or b2-deficient mice. Blood 2001; 97: 1282-1288.

 

Scott LM, Mueller L, Collins SJ. E3, a hematopoietic-specific transcript directly regulated by the retinoic acid receptor alpha. Blood 1996; 88: 2517-2530.

 

Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2b/CBFb proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol. Cell. Biol. 1994; 14: 5558-5568.

 

Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992: 80: 1725-1735.